A Study to Assess the Effects of Single Oral Doses of MK-8527 on the Single-Dose Pharmacokinetics of an Oral Contraceptive (Levonorgestrel and Ethinyl Estradiol) in Healthy Adult Postmenopausal or Oophorectomized Female Subjects
Latest Information Update: 24 Jan 2025
At a glance
- Drugs MK-8527 (Primary) ; Ethinylestradiol/levonorgestrel
- Indications HIV infections
- Focus Adverse reactions
Most Recent Events
- 24 Jan 2025 Status changed to completed.
- 18 Jul 2024 New trial record
- 16 Jul 2024 According to a Merck Sharp & Dohme media release, company will present data from this study at the 25th International AIDS Conference (AIDS 2024), taking place July 22-26, 2024, in Munich, Germany.